BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yao FY, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48:819-827. [PMID: 18688876 DOI: 10.1002/hep.22412] [Cited by in Crossref: 355] [Cited by in F6Publishing: 318] [Article Influence: 27.3] [Reference Citation Analysis]
Number Citing Articles
1 Mazzola A, Costantino A, Petta S, Bartolotta TV, Raineri M, Sacco R, Brancatelli G, Cammà C, Cabibbo G. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncol 2015;11:2923-36. [PMID: 26414336 DOI: 10.2217/fon.15.239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
2 Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, De Simone P, Filipponi F, Bartolozzi C. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation. Radiology. 2010;255:289-300. [PMID: 20308465 DOI: 10.1148/radiol.09090927] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.7] [Reference Citation Analysis]
3 Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States: Liver Allocation in Patients With HCC. Liver Transpl 2010;16:262-78. [DOI: 10.1002/lt.21999] [Cited by in Crossref: 293] [Cited by in F6Publishing: 239] [Article Influence: 24.4] [Reference Citation Analysis]
4 Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25:74-85. [PMID: 27312032 DOI: 10.1016/j.suronc.2016.03.002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 171] [Article Influence: 33.0] [Reference Citation Analysis]
5 Lo C. Downstaging of hepatocellular carcinoma before transplantation: an advance in therapy or just another selection criterion. Am J Transplant. 2008;8:2485-2486. [PMID: 19032218 DOI: 10.1111/j.1600-6143.2008.02466.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
6 Kim DG, Lee JG, Joo DJ, Kim SI, Kim MS. Favourable outcome of pathologic downstaging by locoregional treatment for hepatocellular carcinoma in liver transplantation. Sci Rep 2019;9:10386. [PMID: 31316165 DOI: 10.1038/s41598-019-46871-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010;24:899-919, viii. [PMID: 20937457 DOI: 10.1016/j.idc.2010.07.004] [Cited by in Crossref: 120] [Cited by in F6Publishing: 109] [Article Influence: 12.0] [Reference Citation Analysis]
8 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 972] [Article Influence: 188.2] [Reference Citation Analysis]
9 Kadry Z, Schaefer EW, Uemura T, Shah AR, Schreibman I, Riley TR. Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States. J Hepatol. 2012;56:618-625. [PMID: 22027581 DOI: 10.1016/j.jhep.2011.08.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
10 Doyle MB, Vachharajani N, Maynard E, Shenoy S, Anderson C, Wellen JR, Lowell JA, Chapman WC. Liver transplantation for hepatocellular carcinoma: long-term results suggest excellent outcomes. J Am Coll Surg. 2012;215:19-28; discussion 28-30. [PMID: 22608403 DOI: 10.1016/j.jamcollsurg.2012.02.022] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
11 Ravaioli M, Ercolani G, Neri F, Cescon M, Stacchini G, Gaudio MD, Cucchetti A, Pinna AD. Liver transplantation for hepatic tumors: A systematic review. World J Gastroenterol 2014; 20(18): 5345-5352 [PMID: 24833864 DOI: 10.3748/wjg.v20.i18.5345] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
12 Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology. 2013;266:376-382. [PMID: 23362092 DOI: 10.1148/radiol.12121698] [Cited by in Crossref: 258] [Cited by in F6Publishing: 233] [Article Influence: 32.3] [Reference Citation Analysis]
13 Lu DS, Siripongsakun S, Kyong Lee J, Wei SH, Cheng PM, Sabounchi S, Lee JS, Raman S, Tong MJ, Busuttil RW, Sayre J. Complete tumor encapsulation on magnetic resonance imaging: A potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma: Complete Tumor Encapsulation. Liver Transpl 2013;19:283-91. [DOI: 10.1002/lt.23597] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
14 Casaccia M, Andorno E, Santori G, Fontana I, Varotti G, Ferrari C, Ertreo M, Valente U. Laparoscopic approach for down-staging in hepatocellular carcinoma patients who are candidates for liver transplantation. Transplant Proc 2013;45:2669-71. [PMID: 24034020 DOI: 10.1016/j.transproceed.2013.07.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Maggs JRL, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1113-34. [DOI: 10.1111/j.1365-2036.2012.05072.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
16 Nakao K, Ichikawa T. Recent topics on α-fetoprotein. Hepatol Res. 2013;43:820-825. [PMID: 23347387 DOI: 10.1111/hepr.12052] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
17 Bhardwaj N, Perera MT, Silva MA. Current Treatment Approaches to HCC with a Special Consideration to Transplantation. J Transplant 2016;2016:7926264. [PMID: 27413539 DOI: 10.1155/2016/7926264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
18 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 267] [Article Influence: 30.3] [Reference Citation Analysis]
19 Yoon HM, Kim JH, Kim EJ, Gwon DI, Ko GY, Ko HK. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. J Vasc Interv Radiol. 2013;24:1639-1646. [PMID: 23962438 DOI: 10.1016/j.jvir.2013.06.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
20 Lee HW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol 2016;22:309-18. [PMID: 27729631 DOI: 10.3350/cmh.2016.0042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
21 Dogan S, Gurakar A. Liver Transplantation Update: 2014. Euroasian J Hepatogastroenterol 2015;5:98-106. [PMID: 29201702 DOI: 10.5005/jp-journals-10018-1144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Lei J, Wang W, Yan L. Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization. J Gastrointest Surg 2013;17:1752-9. [PMID: 23959694 DOI: 10.1007/s11605-013-2311-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
23 Sandow T, Pavlus J, Field D, Lacayo E, Cohen E, Lynskey G, Caridi T, Buckley D, Cardella J, Kallakury B, Spies J, Kim AY. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. J Vasc Interv Radiol 2019;30:995-1003. [PMID: 31109853 DOI: 10.1016/j.jvir.2018.12.736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Galastri FL, Nasser F, Affonso BB, Valle LGM, Odísio BC, Motta-Leal Filho JM, Salvalaggio PR, Garcia RG, de Almeida MD, Baroni RH, Wolosker N. Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma. World J Hepatol 2020; 12(1): 21-33 [PMID: 31984118 DOI: 10.4254/wjh.v12.i1.21] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Wong LL, Naugler WE, Schwartz J, Scott DL, Bhattacharya R, Reyes J, Orloff SL. Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis. Clin Transplant. 2013;27:E72-E79. [PMID: 23278701 DOI: 10.1111/ctr.12056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
26 Salgia R, Singal AG. Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America 2014;98:103-18. [DOI: 10.1016/j.mcna.2013.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
27 Brahmania M, Ahmed O, Kelley M, Wong D, Kowgier M, Khalili K, Beecroft R, Renner EL, Shah H, Feld J, Janssen HLA, Sherman M. Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma. Ann Hepatol 2017;16:765-71. [PMID: 28809734 DOI: 10.5604/01.3001.0010.2776] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Kim HD, Song GW, Shim JH, Han S, An J, Moon DB, Kim KM, Lim YS, Ko GY, Hwang S, Lee HC, Yu E, Sung KB, Lee SG. Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma. Hepatol Int 2017;11:209-19. [PMID: 28144812 DOI: 10.1007/s12072-017-9785-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Malek NP, Vogel A, Manns MP. [Multimodality treatment for hepatocellular carcinoma]. Internist (Berl) 2010;51:1374-81. [PMID: 20938626 DOI: 10.1007/s00108-010-2673-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Ravaioli M, Piscaglia F, Cillo U, Brandi G, Sessa M, Germinario G, Golfieri R, Cappelli A, Morelli MC, Siniscalchi A, D'Errico A, Cescon M, Iannone P, Trevisani F. Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations? Liver Cancer 2021;10:394-5. [PMID: 34414126 DOI: 10.1159/000516196] [Reference Citation Analysis]
31 Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND, Feng M. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122-130. [PMID: 29066120 DOI: 10.1016/j.ijrobp.2017.09.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 50] [Article Influence: 16.5] [Reference Citation Analysis]
32 Fidelman N, Johanson C, Kohi MP, Kolli KP, Kohlbrenner RM, Lehrman ED, Taylor AG, Kelley RK, Yao FY, Roberts JP, Kerlan RK. Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve. J Hepatocell Carcinoma 2019;6:93-103. [PMID: 31355158 DOI: 10.2147/JHC.S206979] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Ettorre GM, Santoro R, Puoti C, Sciuto R, Carpanese L, Antonini M, Antonucci G, Maini CL, Miglioresi L, Vennarecci G. Short-term follow-up of radioembolization with yttrium-90 microspheres before liver transplantation: new perspectives in advanced hepatocellular carcinoma. Transplantation. 2010;90:930-931. [PMID: 20962610 DOI: 10.1097/tp.0b013e3181f10f04] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
34 Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125-137. [PMID: 30600478 DOI: 10.1007/s12072-018-9919-1] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 42.5] [Reference Citation Analysis]
35 Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are There Upper Limits in Tumor Burden for Down‐Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All‐Comers Protocol. Hepatology 2019;70:1185-96. [DOI: 10.1002/hep.30570] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
36 Bhoori S, Mazzaferro V. Current challenges in liver transplantation for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:867-79. [DOI: 10.1016/j.bpg.2014.08.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
37 Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F. Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: An outcome analysis. HPB (Oxford). 2012;14:325-332. [PMID: 22487070 DOI: 10.1111/j.1477-2574.2012.00453.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
38 Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014; 20(41): 15007-15017 [PMID: 25386049 DOI: 10.3748/wjg.v20.i41.15007] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
39 Zeng Z, Ren J, O’Neil M, Zhao J, Bridges B, Cox J, Abdulkarim B, Schmitt TM, Kumer SC, Weinman SA. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation. BMC Cancer. 2012;12:584. [PMID: 23216644 DOI: 10.1186/1471-2407-12-584] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
40 Ravaioli M, Odaldi F, Cucchetti A, Trevisani F, Piscaglia F, De Pace V, Bertuzzo VR, Neri F, Golfieri R, Cappelli A, D'Errico A, Cescon M, Del Gaudio M, Fallani G, Siniscalchi A, Morelli MC, Ciccarese F, Di Marco M, Farinati F, Giannini EG, Pinna AD. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. Sci Rep 2019;9:3781. [PMID: 30846792 DOI: 10.1038/s41598-019-40543-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Pavel M, Sanchez Cabus S, Crespo G, Ferrer J, Fondevila C, Fuster J, Garcia-valdecasas J. Role of Adult Living Donor Liver Transplantation in the Treatment of Hepatocellular Carcinoma Within and Beyond Milan Criteria: A Comparative Study. Transplantation Proceedings 2018;50:1386-95. [DOI: 10.1016/j.transproceed.2018.02.093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
43 Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2013;2:435-44. [PMID: 24236684 DOI: 10.2217/cer.13.37] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
44 Shaker MK, Montasser IF, Sakr M, Elgharib M, Dabbous HM, Ebada H, Dorry AE, Bahaa M, Meteini ME. Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt. J Hepatocell Carcinoma 2018;5:29-36. [PMID: 29520343 DOI: 10.2147/JHC.S147098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Russo MW. The Care of the Postliver Transplant Patient. J Clin Gastroenterol 2017;51:683-92. [PMID: 28796003 DOI: 10.1097/MCG.0000000000000886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
46 Khorsandi SE, Heaton N. Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg 2012;2012:154056. [PMID: 23197879 DOI: 10.1155/2012/154056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
47 Shi XJ, Jin X, Wang MQ, Wei LX, Ye HY, Liang YR, Luo Y, Dong JH. Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation. Hepatobiliary Pancreat Dis Int. 2011;10:143-150. [PMID: 21459720 DOI: 10.1016/s1499-3872(11)60023-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
48 Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:987-999. [PMID: 22429190 DOI: 10.1111/j.1365-2036.2012.05060.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 1.9] [Reference Citation Analysis]
49 Tanaka K. Resection versus transplantation for hepatocellular carcinoma exceeding Milan criteria within increasing donor shortage. Hepatobiliary Surg Nutr 2017;6:280-3. [PMID: 28848755 DOI: 10.21037/hbsn.2017.03.14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC. Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation. Ann Surg Oncol. 2011;18:2638-2646. [PMID: 21584831 DOI: 10.1245/s10434-011-1779-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
51 Abou-alfa GK, Jarnagin W, Lowery M, D'angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1373-1396.e8. [DOI: 10.1016/b978-1-4557-2865-7.00080-1] [Reference Citation Analysis]
52 Kelley RK, Yao F. Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: a new strategy? J Hepatol. 2012;56:14-16. [PMID: 21872558 DOI: 10.1016/j.jhep.2011.06.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
53 Lee TK, Kwon J, Na KS, Jeong HS, Hwang H, Oh PS, Kim DH, Jang KY, Lim ST, Sohn MH, Jeong HJ. Evaluation of Selective Arterial Embolization Effect by Chitosan Micro-Hydrogels in Hindlimb Sarcoma Rodent Models Using Various Imaging Modalities. Nucl Med Mol Imaging 2015;49:191-9. [PMID: 26279692 DOI: 10.1007/s13139-014-0316-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
54 Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl. 2012;18:423-433. [PMID: 22250078 DOI: 10.1002/lt.23385] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
55 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 90.0] [Reference Citation Analysis]
56 Bauschke A, Altendorf-Hofmann A, Ardelt M, Kissler H, Tautenhahn HM, Settmacher U. Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis. J Cancer Res Clin Oncol 2020;146:1819-27. [PMID: 32356179 DOI: 10.1007/s00432-020-03215-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
57 Song DS, Nam SW, Bae SH, Kim JD, Jang JW, Song MJ, Lee SW, Kim HY, Lee YJ, Chun HJ, You YK, Choi JY, Yoon SK. Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2015; 21(8): 2395-2404 [PMID: 25741147 DOI: 10.3748/wjg.v21.i8.2395] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
58 Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013;19:1343-1353. [PMID: 24285611 DOI: 10.1002/lt.23753] [Cited by in Crossref: 103] [Cited by in F6Publishing: 82] [Article Influence: 14.7] [Reference Citation Analysis]
59 Kulik LM, Fisher RA, Rodrigo DR, Brown RS, Freise CE, Shaked A, Everhart JE, Everson GT, Hong JC, Hayashi PH, Berg CL, Lok AS; A2ALL Study Group. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant. 2012;12:2997-3007. [PMID: 22994906 DOI: 10.1111/j.1600-6143.2012.04272.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 10.2] [Reference Citation Analysis]
60 Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, Thomas Purcell W, Biggins SW. Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl. 2015;21:1543-1552. [PMID: 26457885 DOI: 10.1002/lt.24356] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
61 Lee V, Seong J, Yoon S, Wong T, Wang B, Zhang J, Chiang C, Ho P, Dawson L. Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. Clinical Oncology 2019;31:560-9. [DOI: 10.1016/j.clon.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19:23-43. [PMID: 25454295 DOI: 10.1016/j.cld.2014.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
63 Györi GP, Felsenreich DM, Silberhumer GR, Soliman T, Berlakovich GA. Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation. Eur Surg 2017;49:236-43. [PMID: 29104589 DOI: 10.1007/s10353-017-0487-8] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
64 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(11)70175-9.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Feng K, Ma KS. Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 5987-5998 [PMID: 24876721 DOI: 10.3748/wjg.v20.i20.5987] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
66 Ei S, Hibi T, Tanabe M, Itano O, Shinoda M, Kitago M, Abe Y, Yagi H, Okabayashi K, Sugiyama D, Wakabayashi G, Kitagawa Y. Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. Ann Surg Oncol. 2015;22:1294-1300. [PMID: 25287439 DOI: 10.1245/s10434-014-4114-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
67 Magnetta MJ, Xing M, Zhang D, Kim HS. The Effect of Bridging Locoregional Therapy and Sociodemographics on Survival in Hepatocellular Carcinoma Patients Undergoing Orthotopic Liver Transplantation: A United Network for Organ Sharing Population Study. J Vasc Interv Radiol 2016;27:1822-8. [PMID: 27692856 DOI: 10.1016/j.jvir.2016.07.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
68 Vivarelli M, Risaliti A. Liver transplantation for hepatocellular carcinoma on cirrhosis: Strategies to avoid tumor recurrence. World J Gastroenterol 2011; 17(43): 4741-4746 [PMID: 22147974 DOI: 10.3748/wjg.v17.i43.4741] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
69 Wörns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S302-S309. [PMID: 20547319 DOI: 10.1016/S1590-8658(10)60521-X] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
70 Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg. 2011;98:1201-1208. [PMID: 21618496 DOI: 10.1002/bjs.7561] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
71 Roayaie K, Roayaie S. Liver transplant for hepatocellular cancer: very small tumors, very large tumors, and waiting time. Clin Liver Dis. 2014;18:603-612. [PMID: 25017078 DOI: 10.1016/j.cld.2014.05.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
72 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7(4): 673-687 [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
73 Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015; 7(3): 566-574 [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
74 Fan ST, Poon RT, Yeung C, Lam CM, Lo CM, Yuen WK, Ng KK, Liu CL, Chan SC. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. Br J Surg. 2011;98:1292-1300. [PMID: 21656513 DOI: 10.1002/bjs.7583] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 7.4] [Reference Citation Analysis]
75 Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M, Toombs B, Round M, Moore W, Mieles L. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl. 2010;16:289-299. [PMID: 20209588 DOI: 10.1002/lt.21994] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
76 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
77 Kim R, Menon N, Aucejo F. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. Med Oncol 2011;28:1044-7. [DOI: 10.1007/s12032-010-9625-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
78 Kim PTW, Onaca N, Chinnakotla S, Davis GL, Jennings LW, Mckenna GJ, Ruiz RM, Levy MF, Goldstein R, Klintmalm GB. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. Clin Transplant 2013;27:311-8. [DOI: 10.1111/ctr.12089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
79 Ravaioli M, Cucchetti A, Cescon M, Piscaglia F, Ercolani G, Trevisani F, Pinna AD. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria (Br J Surg 2011; 98: 1201-1208). Br J Surg. 2011;98:1674; author reply 1675. [PMID: 21964691 DOI: 10.1002/bjs.7728] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
80 Sonnenday CJ. Recurrent hepatocellular carcinoma after living donor liver transplantation: a preventable problem or an acceptable risk? Ann Surg Oncol 2010;17:2262-3. [PMID: 20431956 DOI: 10.1245/s10434-010-1099-8] [Reference Citation Analysis]
81 Bargellini I, Battaglia V, Caramella D, Bartolozzi C. Imaging in Hepatocellular Carcinoma: Radiologic Assessment. In: Berliner L, Lemke HU, editors. An Information Technology Framework for Predictive, Preventive and Personalised Medicine. Cham: Springer International Publishing; 2015. pp. 33-44. [DOI: 10.1007/978-3-319-12166-6_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
82 Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry. Liver Transpl. 2014;20:1045-1056. [PMID: 24838471 DOI: 10.1002/lt.23917] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 8.4] [Reference Citation Analysis]
83 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(1170175-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis 2021;25:19-33. [PMID: 33978578 DOI: 10.1016/j.cld.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology 2013;201:80-96. [DOI: 10.2214/ajr.13.10706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 6.6] [Reference Citation Analysis]
86 Müller V, Förtsch T, Gündel M, Croner RS, Langheinrich M, Yedibela S, Lohmüller C, Küffner M, Hohenberger W, Perrakis A. Long-term outcome of liver transplantation as treatment modality in patients with hepatocellular carcinoma in cirrhosis: a single-center experience. Transplant Proc 2013;45:1957-60. [PMID: 23769082 DOI: 10.1016/j.transproceed.2013.01.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
87 Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma: . Current Opinion in Gastroenterology 2010;26:189-95. [DOI: 10.1097/mog.0b013e3283383ca5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
88 Skagen C, Lucey M, Said A. Liver transplantation: an update 2009: . Current Opinion in Gastroenterology 2009;25:202-8. [DOI: 10.1097/mog.0b013e3283299652] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
89 Tuci F, Vitale A, D’Amico F, Gringeri E, Neri D, Zanus G, Bassi D, Polacco M, Boetto R, Lodo E. Survival benefit of transplantation for recurrence of hepatocellular carcinoma after liver resection. Transplant Proc. 2014;46:2287-2289. [PMID: 25242770 DOI: 10.1016/j.transproceed.2014.07.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
90 Kim HD, Shim JH, Kim GA, Shin YM, Yu E, Lee SG, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. J Hepatol 2015;62:1076-84. [PMID: 25529626 DOI: 10.1016/j.jhep.2014.12.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
91 Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144-1165. [PMID: 24716201 DOI: 10.1002/hep.26972] [Cited by in Crossref: 429] [Cited by in F6Publishing: 321] [Article Influence: 61.3] [Reference Citation Analysis]
92 Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand? World J Gastroenterol 2014; 20(18): 5308-5319 [PMID: 24833861 DOI: 10.3748/wjg.v20.i18.5308] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
93 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
94 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
95 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 2.8] [Reference Citation Analysis]
96 Bova V, Miraglia R, Maruzzelli L, Vizzini GB, Luca A. Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies. Cardiovasc Intervent Radiol 2013;36:433-9. [PMID: 22864644 DOI: 10.1007/s00270-012-0458-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
97 Zhang Y, Huang G, Wang Y, Liang L, Peng B, Fan W, Yang J, Huang Y, Yao W, Li J. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. Oncologist 2016;21:1442-9. [PMID: 27486202 DOI: 10.1634/theoncologist.2016-0094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
98 Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World J Gastroenterol 2017; 23(18): 3195-3204 [PMID: 28566879 DOI: 10.3748/wjg.v23.i18.3195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection. J Gastrointest Surg. 2013;17:702-711. [PMID: 23225107 DOI: 10.1007/s11605-012-2087-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
100 Schmitt TM, Kumer SC, Shah N, Argo CK, Northup PG. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions. Annals of Hepatology 2010;9:390-6. [DOI: 10.1016/s1665-2681(19)31614-x] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
101 Tan CHN, Yu Y, Tan YRN, Lim BLK, Iyer SG, Madhavan K, Kow AWC. Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere? Ann Hepatobiliary Pancreat Surg 2018;22:27-35. [PMID: 29536053 DOI: 10.14701/ahbps.2018.22.1.27] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
102 Abou-alfa GK, Marrero J, Renz J, Lencioni R. Hepatocellular Carcinoma Tumor Board: Making Sense of the Technologies. American Society of Clinical Oncology Educational Book 2015. [DOI: 10.14694/edbook_am.2015.35.e213] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Lin Y, Chapman WC. Towards more effective liver allocation criteria for hepatocellular carcinoma: Tumor response to locoregional therapy. Ann Surg Oncol. 2011;18:2416-2418. [PMID: 21590451 DOI: 10.1245/s10434-011-1786-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Mumtaz K, Patel N, Modi RM, Patel V, Hinton A, Hanje J, Black SM, Krishna S. Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey. Hepatobiliary Pancreat Dis Int 2017;16:624-30. [PMID: 29291782 DOI: 10.1016/S1499-3872(17)60077-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Chan SC, Sharr WW, Chok KS, Chan AC, Lo CM. Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts. Transplantation. 2013;96:995-999. [PMID: 23924774 DOI: 10.1097/tp.0b013e3182a339a7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
106 Best J, Schotten C, Theysohn JM, Wetter A, Müller S, Radünz S, Schulze M, Canbay A, Dechêne A, Gerken G. Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol 2017;30:23-32. [PMID: 28042235 DOI: 10.20524/aog.2016.0092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
107 Amano H, Tashiro H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Itamoto T, Asahara T, Ohdan H. Significance of Platelet Count in the Outcomes of Hepatectomized Patients with Hepatocellular Carcinoma Exceeding the Milan Criteria. J Gastrointest Surg 2011;15:1173-81. [DOI: 10.1007/s11605-011-1538-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
108 Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. Transpl Int 2020;33:567-75. [PMID: 31994238 DOI: 10.1111/tri.13586] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
109 Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol 2013; 19(27): 4400-4408 [PMID: 23885153 DOI: 10.3748/wjg.v19.i27.4400] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
110 Lei J, Wang W, Yan L. Downstaging Advanced Hepatocellular Carcinoma to the Milan Criteria May Provide a Comparable Outcome to Conventional Milan Criteria. J Gastrointest Surg 2013;17:1440-6. [DOI: 10.1007/s11605-013-2229-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
111 Bargellini I. Hepatocellular carcinoma: MR staging and therapeutic decisions. Abdom Imaging 2012;37:231-8. [PMID: 21479803 DOI: 10.1007/s00261-011-9735-8] [Reference Citation Analysis]
112 Chan SC, Fan ST, Chok KS, Cheung TT, Chan AC, Fung JY, Poon RT, Lo CM. Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion. Hepatol Int. 2012;6:646-656. [PMID: 22016140 DOI: 10.1007/s12072-011-9318-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
113 Sá GPD, Carlotto JRM, Vicentine FPP, Romero L, Tejada DFP, Salzedas AA Netto, Lopes GJ Filho, Gonzalez AM. Evaluation of the treatment of the hepatocarcinoma nodules in the patients in waiting list for liver transplant. Rev Col Bras Cir 2017;44:360-6. [PMID: 29019539 DOI: 10.1590/0100-69912017004010] [Reference Citation Analysis]
114 Grant D, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST. Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? Liver Transpl. 2011;17 Suppl 2:S133-S138. [PMID: 21634006 DOI: 10.1002/lt.22348] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
115 Neuberger J. Liver-cell cancer and transplantation. The Lancet Oncology 2009;10:5-7. [DOI: 10.1016/s1470-2045(08)70318-8] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
116 Iñarrairaegui M, Pardo F, Bilbao J, Rotellar F, Benito A, D'avola D, Herrero J, Rodriguez M, Martí P, Zozaya G, Dominguez I, Quiroga J, Sangro B. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 2012;38:594-601. [DOI: 10.1016/j.ejso.2012.02.189] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 7.8] [Reference Citation Analysis]
117 Bürger C, Maschmeier M, Hüsing-Kabar A, Wilms C, Köhler M, Schmidt M, Schmidt HH, Kabar I. Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation. Can J Gastroenterol Hepatol 2019;2019:5796074. [PMID: 30729099 DOI: 10.1155/2019/5796074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
119 Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, Mentha G, Combescure C. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology. 2012;56:149-156. [PMID: 22271250 DOI: 10.1002/hep.25603] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 8.2] [Reference Citation Analysis]
120 Ma KW, Cheung TT. When to consider liver transplantation in hepatocellular carcinoma patients? Hepat Oncol. 2017;4:15-24. [PMID: 30191050 DOI: 10.2217/hep-2016-0010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
121 Kemmer NM, Neff GW. Liver Transplantation Trends and Survival in the Asian Population. Transplantation 2009;88:392-4. [DOI: 10.1097/tp.0b013e3181aed68c] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
122 Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol 2015; 7(26): 2648-2663 [PMID: 26609342 DOI: 10.4254/wjh.v7.i26.2648] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 19.3] [Reference Citation Analysis]
123 Shrager B, Jibara GA, Tabrizian P, Schwartz ME, Labow DM, Hiotis S. Resection of large hepatocellular carcinoma (≥10 cm): A unique western perspective: Resection of Large HCC in the West. J Surg Oncol 2013;107:111-7. [DOI: 10.1002/jso.23246] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
124 Dufour J, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho R. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Annals of Oncology 2013;24:24-9. [DOI: 10.1093/annonc/mdt054] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
125 Sciarra A, Ronot M, Di Tommaso L, Raschioni C, Castera L, Belghiti J, Bedossa P, Vilgrain V, Roncalli M, Paradis V. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver Int. 2015;Epub ahead of print. [PMID: 25865109 DOI: 10.1111/liv.12844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
126 Ameli S, Shaghaghi M, Ghasabeh MA, Pandey P, Hazhirkarzar B, Habibabadi RR, Ghadimi M, Khoshpouri P, Pandey A, Kamel IR. Does the change in volumetric functional MR metrics post-TACE predict histopathologic grading of hepatocellular carcinoma? Eur Radiol 2020;30:6709-20. [DOI: 10.1007/s00330-020-07052-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
127 Nakamura H, Kawano Y, Miyanishi K, Ishikawa K, Kubo T, Tanaka S, Takada K, Kobune M, Harada K, Kawamura N, Shimamura T, Kanno-Okada H, Kato J. Successful Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Chemoembolization followed by Radical Liver Transplantation in a Patient with Severe Liver Damage. Case Rep Oncol 2019;12:289-96. [PMID: 31097938 DOI: 10.1159/000499703] [Reference Citation Analysis]
128 Chan SC, Fan ST. Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation. Hepatobiliary Surg Nutr 2013;2:84-8. [PMID: 24570921 DOI: 10.3978/j.issn.2304-3881.2012.12.04] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
129 Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014;20:1221-1228. [PMID: 25045002 DOI: 10.1002/lt.23945] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
130 Piñero F, Tisi Baña M, de Ataide EC, Hoyos Duque S, Marciano S, Varón A, Anders M, Zerega A, Menéndez J, Zapata R, Muñoz L, Padilla Machaca M, Soza A, McCormack L, Poniachik J, Podestá LG, Gadano A, Boin IS, Duvoux C, Silva M; Latin American Liver Research, Education and Awareness Network (LALREAN). Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int 2016;36:1657-67. [PMID: 27169841 DOI: 10.1111/liv.13159] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
131 Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol 2015; 7(8): 1020-1029 [PMID: 26052391 DOI: 10.4254/wjh.v7.i8.1020] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 13.5] [Reference Citation Analysis]
132 Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 2009;22:869-75. [PMID: 19386075 DOI: 10.1111/j.1432-2277.2009.00882.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
133 Ertel AE, Shah SA. Surgical Approaches to Hepatocellular Carcinoma. Semin Roentgenol 2016;51:88-94. [PMID: 27105963 DOI: 10.1053/j.ro.2016.02.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
134 Sharr WW, Chan SC, Lo CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation. 2014;97 Suppl 8:S10-S17. [PMID: 24849822 DOI: 10.1097/01.tp.0000446267.19148.21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
135 Bhoori S, Sposito C, Germini A, Coppa J, Mazzaferro V. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int. 2010;23:712-722. [PMID: 20492616 DOI: 10.1111/j.1432-2277.2010.01111.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
136 Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I, Mocchegiani F, Vecchi A, Montalti R, Benedetti A, Risaliti A, Vivarelli M. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 2013; 19(34): 5622-5632 [PMID: 24039354 DOI: 10.3748/wjg.v19.i34.5622] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
137 Kumaran V. Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S97-S103. [PMID: 25755618 DOI: 10.1016/j.jceh.2014.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
138 Oligane HC, Close ON, Xing M, Kim HS. Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma. Transplant Rev (Orlando) 2017;31:136-43. [PMID: 28214240 DOI: 10.1016/j.trre.2017.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
139 Choi JY. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. Oncology. 2011;81 Suppl 1:141-147. [PMID: 22212948 DOI: 10.1159/000333277] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
140 de Ville de Goyet J, Meyers RL, Tiao GM, Morland B. Beyond the Milan criteria for liver transplantation in children with hepatic tumours. The Lancet Gastroenterology & Hepatology 2017;2:456-62. [DOI: 10.1016/s2468-1253(17)30084-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 4.3] [Reference Citation Analysis]
141 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
142 Abreu P, Gorgen A, Griffiths C, Ivanics T, Sapisochin G. Downstaging and Expanded Criteria Hepatocellular Carcinoma Liver Transplantation. Curr Hepatology Rep 2019;18:400-7. [DOI: 10.1007/s11901-019-00492-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, Brouquet A, Adams RB; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:289-299. [PMID: 20590901 DOI: 10.1111/j.1477-2574.2010.00181.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 11.1] [Reference Citation Analysis]
144 Chang WT, Kao WY, Chau GY, Su CW, Lei HJ, Wu JC, Hsia CY, Lui WY, King KL, Lee SD. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery. 2012;152:809-820. [PMID: 22766361 DOI: 10.1016/j.surg.2012.03.024] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 6.8] [Reference Citation Analysis]
145 Song GW, Hwang S, Lee SG. [Liver transplantation in patients with hepatocellular carcinoma]. Korean J Gastroenterol. 2010;55:350-360. [PMID: 20571302 DOI: 10.4166/kjg.2010.55.6.350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
146 Ettorre GM, Levi Sandri GB, Laurenzi A, Colasanti M, Meniconi RL, Lionetti R, Santoro R, Lepiane P, Sciuto R, Pizzi G, Cianni R, Golfieri R, D'Offizi G, Pellicelli AM, Antonini M, Vennarecci G. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg 2017;41:241-9. [PMID: 27495316 DOI: 10.1007/s00268-016-3682-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
147 Levi DM, Nishida S. Liver Transplantation for Hepatocellular Carcinoma: Lessons Learned and Future Directions. Clinics in Liver Disease 2011;15:717-25. [DOI: 10.1016/j.cld.2011.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
148 Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant. 2011;11:2031-2035. [PMID: 21831154 DOI: 10.1111/j.1600-6143.2011.03689.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 7.3] [Reference Citation Analysis]
149 Kwan SW, Fidelman N, Ma E, Kerlan RK Jr, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012;18:727-736. [PMID: 22344899 DOI: 10.1002/lt.23413] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 8.2] [Reference Citation Analysis]
150 Kishi Y, Shimada K, Nara S, Esaki M, Kosuge T. Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma. World J Hepatol 2014; 6(12): 836-843 [PMID: 25544870 DOI: 10.4254/wjh.v6.i12.836] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
151 Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-292. [PMID: 23507917 DOI: 10.1097/mog.0b013e32835ff1cf] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
152 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
153 Mendizabal M, Reddy KR. Current Management of Hepatocellular Carcinoma. Medical Clinics of North America 2009;93:885-900. [DOI: 10.1016/j.mcna.2009.03.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
154 Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52:930-936. [PMID: 20385428 DOI: 10.1016/j.jhep.2009.12.032] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 8.0] [Reference Citation Analysis]
155 Levi DM, Tzakis AG, Martin P, Nishida S, Island E, Moon J, Selvaggi G, Tekin A, Madrazo BL, Narayanan G, Garcia MT, Feun LG, Tryphonopoulos P, Skartsis N, Livingstone AS. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg. 2010;210:727-734, 735-736. [PMID: 20421039 DOI: 10.1016/j.jamcollsurg.2010.01.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
156 Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220:416-427. [PMID: 25690672 DOI: 10.1016/j.jamcollsurg.2014.12.025] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 18.9] [Reference Citation Analysis]
157 Dumitra TC, Dumitra S, Metrakos PP, Barkun JS, Chaudhury P, Deschênes M, Paraskevas S, Hassanain M, Tchervenkov JI. Pretransplantation α-fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation 2013;95:228-33. [PMID: 23222895 DOI: 10.1097/TP.0b013e31827743d7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
158 Hibi T, Shinoda M, Itano O, Kitagawa Y. Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine. Organogenesis 2014;10:241-9. [PMID: 24836922 DOI: 10.4161/org.29245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
159 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
160 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
161 Wong R, Frenette C, Gish R. Hepatocellular carcinoma: locoregional and targeted therapies. Gastroenterol Clin North Am. 2011;40:599-610. [PMID: 21893276 DOI: 10.1016/j.gtc.2011.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
162 Levitsky J, Guckelberger O. Meeting report of the 2011 Joint International Congress of the International Liver Transplantation Society, the European Liver and Intestine Transplant Association, and the Liver Intensive Care Group of Europe. Liver Transpl 2012;18:282-9. [PMID: 22139868 DOI: 10.1002/lt.22470] [Reference Citation Analysis]
163 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Kedarisetty CK, Bal S, Parida S, Jain M, Bhadoria AS, Varghese J, Venkataraman J. Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience. J Clin Exp Hepatol 2021;11:299-304. [PMID: 33994712 DOI: 10.1016/j.jceh.2020.10.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Elshamy M, Aucejo F, Menon KVN, Eghtesad B. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria. World J Hepatol 2016; 8(21): 874-880 [PMID: 27478537 DOI: 10.4254/wjh.v8.i21.874] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
166 Lee SG, Moon DB. Living donor liver transplantation for hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:165-179. [PMID: 22941020 DOI: 10.1007/978-3-642-16037-0_11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
167 Iguchi T, Shirabe K, Aishima S, Wang H, Fujita N, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T. New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation. Transplantation. 2015;99:1236-1242. [PMID: 25427164 DOI: 10.1097/tp.0000000000000489] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
168 Zhang W, Xu AH, Wang W, Wu YH, Sun QL, Shu C. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation. BMC Cancer 2019;19:1041. [PMID: 31690274 DOI: 10.1186/s12885-019-6265-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
169 Chan SC, Cheung TT, Chan AC, Chok KS, Sharr WW, Fung JY, Liu CL, Fan ST, Lo CM. New insights after the first 1000 liver transplantations at The University of Hong Kong. Asian J Surg 2016;39:202-10. [PMID: 26143970 DOI: 10.1016/j.asjsur.2015.03.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
170 González Huezo MS, Sánchez Ávila JF. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Revista de Gastroenterología de México 2014;79:250-62. [DOI: 10.1016/j.rgmx.2014.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
171 Mehta N, Fidelman N, Sarkar M, Yao FY. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:572-578. [PMID: 23333661 DOI: 10.1016/j.cgh.2012.12.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
172 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
173 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 22.5] [Reference Citation Analysis]
174 Kulik L. Criteria for liver transplantation in hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2015;6:100-2. [PMID: 31041000 DOI: 10.1002/cld.499] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
175 Takada Y, Uemoto S. Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci 2010;17:527-32. [PMID: 19707711 DOI: 10.1007/s00534-009-0162-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
176 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
177 Levi Sandri GB, Ettorre GM, Giannelli V, Colasanti M, Sciuto R, Pizzi G, Cianni R, D'Offizi G, Antonini M, Vennarecci G, Lucatelli P. Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. Transl Gastroenterol Hepatol 2017;2:98. [PMID: 29264436 DOI: 10.21037/tgh.2017.11.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
178 Kornberg A, Witt U, Matevossian E, Küpper B, Assfalg V, Drzezga A, Hüser N, Wildgruber M, Friess H. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One. 2013;8:e53960. [PMID: 23349774 DOI: 10.1371/journal.pone.0053960] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
179 Ogawa K, Kaido T, Okajima H, Fujimoto Y, Yoshizawa A, Yagi S, Hori T, Iida T, Takada Y, Uemoto S. Impact of pretreatments on outcomes after living donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2019;26:73-81. [PMID: 30561147 DOI: 10.1002/jhbp.602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
180 Kim YJ, Jang H, Lee K, Park S, Min SG, Hong C, Park JH, Lee K, Kim J, Hong W, Jung H, Liu Y, Rajkumar H, Khened M, Krishnamurthi G, Yang S, Wang X, Han CH, Kwak JT, Ma J, Tang Z, Marami B, Zeineh J, Zhao Z, Heng PA, Schmitz R, Madesta F, Rösch T, Werner R, Tian J, Puybareau E, Bovio M, Zhang X, Zhu Y, Chun SY, Jeong WK, Park P, Choi J. PAIP 2019: Liver cancer segmentation challenge. Med Image Anal 2021;67:101854. [PMID: 33091742 DOI: 10.1016/j.media.2020.101854] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
181 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Vutien P, Dodge J, Bambha KM, Nordstrom EM, Gralla J, Campbell K, Levek C, Nydam T, Fix O, Ioannou G, Biggins SW. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma–Initial, Maximum, Last Classification. Liver Transpl 2019;25:559-70. [DOI: 10.1002/lt.25422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
183 Livraghi T. Radiofrequency ablation of hepatocellular carcinoma. Surg Oncol Clin N Am. 2011;20:281-299, viii. [PMID: 21377584 DOI: 10.1016/j.soc.2010.11.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
184 Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J; on behalf of the European Hepatocellular Cancer Liver Transplant Study Group. Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation: Alpha-Fetoprotein Increase and m RECIST Progression. Liver Transpl 2013;19:1108-18. [DOI: 10.1002/lt.23706] [Cited by in Crossref: 121] [Cited by in F6Publishing: 124] [Article Influence: 15.1] [Reference Citation Analysis]
185 Berumen J, Hemming A. Liver transplantation for hepatocellular carcinoma. Abdom Radiol 2018;43:185-92. [DOI: 10.1007/s00261-017-1217-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
186 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Ha Y, Han S, Shim JH, Ko GY, Yoon HK, Sung KB, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1093-1101.e1. [PMID: 26077020 DOI: 10.1016/j.jvir.2015.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
188 Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951. [PMID: 24797281 DOI: 10.1002/lt.23904] [Cited by in Crossref: 145] [Cited by in F6Publishing: 138] [Article Influence: 20.7] [Reference Citation Analysis]
189 Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58. [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100] [Cited by in Crossref: 810] [Cited by in F6Publishing: 813] [Article Influence: 73.6] [Reference Citation Analysis]
190 Chapman WC, Garcia-Aroz S, Vachharajani N, Fowler K, Saad N, Lin Y, Wellen J, Tan B, Khan AS, Doyle MB. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg. 2017;224:610-621. [PMID: 28069527 DOI: 10.1016/j.jamcollsurg.2016.12.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
191 Bhat M, Hassanain M, Simoneau E, Tzimas GN, Chaudhury P, Deschenes M, Valenti D, Ghali P, Wong P, Cabrera T. Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinoma. Curr Oncol. 2013;20:265-272. [PMID: 24155631 DOI: 10.3747/co.20.1270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
192 Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21:947-56. [PMID: 32615109 DOI: 10.1016/S1470-2045(20)30224-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 27.0] [Reference Citation Analysis]
193 Kuo ZK, Lin MW, Lu IH, Yao HJ, Wu HC, Wang CC, Lin SH, Wu SY, Tong TS, Cheng YC, Yen JH, Ko CH, Chiou SJ, Pan IH, Tseng HW. Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract. BMC Complement Altern Med 2016;16:277. [PMID: 27502492 DOI: 10.1186/s12906-016-1250-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
194 Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl. 2010;16:925-929. [PMID: 20658555 DOI: 10.1002/lt.22103] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 9.0] [Reference Citation Analysis]
195 Marin D, Cappabianca S, Serra N, Sica A, Lassandro F, D'Angelo R, La Porta M, Fiore F, Somma F. CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review. Gastroenterol Res Pract 2015;2015:670965. [PMID: 26798332 DOI: 10.1155/2015/670965] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
196 Cascales Campos PA, Romero PR, Gonzalez R, Zambudio AR, Martinez Frutos IM, de la Peña J, Bueno FS, Robles Campos R, Miras M, Pons Miñano JA, Sanmartin Monzo A, Domingo J, Bixquert Montagud V, Parrilla Paricio P. Improving the waiting list by using 75-year-old donors for recipients with hepatocellular carcinoma. Transplant Proc 2010;42:627-30. [PMID: 20304209 DOI: 10.1016/j.transproceed.2010.02.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
197 Piñero F, Fauda M, Quiros R, Mendizabal M, González-Campaña A, Czerwonko D, Barreiro M, Montal S, Silberman E, Coronel M, Cacheiro F, Raffa P, Andriani O, Silva M, Podestá LG. Predicting early discharge from hospital after liver transplantation (ERDALT) at a single center: a new model. Ann Hepatol 2015;14:845-55. [PMID: 26436356 DOI: 10.5604/16652681.1171770] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
198 Cascales-campos P, Ramírez P, Lopez V, Gonzalez R, Saenz-mateos L, Llacer E, Sánchez Bueno F, Robles R, Pons J, Capel A, Frutos L, Navarro J, Muñoz-ramon P, Parrilla P. Prognostic Value of 18-Fluorodeoxyglucose-Positron Emission Tomography After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Undergoing Orthotopic Liver Transplantation. Transplantation Proceedings 2015;47:2374-6. [DOI: 10.1016/j.transproceed.2015.08.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
199 Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 2018;68:449-61. [PMID: 29476694 DOI: 10.1002/hep.29855] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 18.0] [Reference Citation Analysis]
200 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 146] [Article Influence: 38.8] [Reference Citation Analysis]
201 Earl TM, Chapman WC. Transplantation for hepatocellular carcinoma: the North American experience. Recent Results Cancer Res 2013;190:145-64. [PMID: 22941019 DOI: 10.1007/978-3-642-16037-0_10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
202 Masuoka HC, Rosen CB. Liver Transplantation for Hepatocellular Carcinoma: Expanding Frontiers and Building Bridges. Clinics in Liver Disease 2011;15:385-93. [DOI: 10.1016/j.cld.2011.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
203 Lysy PA, Smets F, Sibille C, Najimi M, Sokal EM. Human skin fibroblasts: From mesodermal to hepatocyte-like differentiation. Hepatology. 2007;46:1574-1585. [PMID: 17969047 DOI: 10.1002/hep.28139] [Cited by in Crossref: 82] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
204 Sommer CM, Stampfl U, Kauczor HU, Pereira PL. [National S3 guidelines on hepatocellular carcinoma]. Radiologe 2014;54:642-53. [PMID: 25047521 DOI: 10.1007/s00117-014-2656-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
205 Piñero F, Marciano S, Anders M, Orozco Ganem F, Zerega A, Cagliani J, Andriani O, de Santibañes E, Gil O, Podestá LG, Mccormack L, Gadano A, Silva M. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina: . European Journal of Gastroenterology & Hepatology 2016;28:421-7. [DOI: 10.1097/meg.0000000000000551] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
206 Chan SC. Liver transplantation for hepatocellular carcinoma. Liver Cancer 2013;2:338-44. [PMID: 24400221 DOI: 10.1159/000343849] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
207 Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814-819. [PMID: 21334400 DOI: 10.1016/j.jhep.2010.12.040] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 11.9] [Reference Citation Analysis]
208 Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58:609-618. [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 11.0] [Reference Citation Analysis]
209 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
210 Fortune BE, Umman V, Gilliland T, Emre S. Liver transplantation for hepatocellular carcinoma: a surgical perspective. J Clin Gastroenterol 2013;47 Suppl:S37-42. [PMID: 23632344 DOI: 10.1097/MCG.0b013e318286ff8e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
211 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3499] [Article Influence: 404.7] [Reference Citation Analysis]
212 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 20.0] [Reference Citation Analysis]
213 Cheung TT, Ma KW, She WH. A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis. Hepatobiliary Surg Nutr 2021;10:193-209. [PMID: 33898560 DOI: 10.21037/hbsn.2020.03.11] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G. Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study. Int J Hepatol. 2011;2011:974514. [PMID: 21994880 DOI: 10.4061/2011/974514] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
215 Ravaioli M, Grazi GL, Cescon M, Trevisani F, Piscaglia F, Ercolani G, Pinna AD. Down-staging of hepatocellular carcinoma prior to liver transplantation: the power of selection. Hepatology 2009;49:1056. [PMID: 19241485 DOI: 10.1002/hep.22629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
216 Jiang G, Ling S, Zhan Q, Zhuang L, Xu X. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplant Rev (Orlando) 2021;35:100606. [PMID: 33636480 DOI: 10.1016/j.trre.2021.100606] [Reference Citation Analysis]
217 Vitale A, Scolari F, Bertacco A, Gringeri E, D'Amico F, Bassi D, D'Amico FE, Angeli P, Burra P, Lai Q, Cillo U. Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or "Wait and See" Strategy? Cancers (Basel) 2021;13:2406. [PMID: 34067521 DOI: 10.3390/cancers13102406] [Reference Citation Analysis]
218 Na GH, Kim EY, Hong TH, You YK, Kim DG. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma. HPB (Oxford). 2016;18:98-106. [PMID: 26776857 DOI: 10.1016/j.hpb.2015.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
219 Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation: Monitoring Patients with Hepatocellular Carcinoma. Liver Transpl 2011;17:S117-27. [DOI: 10.1002/lt.22334] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
220 Green TJ, Rochon PJ, Chang S, Ray CE, Winston H, Ruef R, Kreidler SM, Glueck DH, Shulman BC, Brown AC. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization. J Vasc Interv Radiol. 2013;24:1613-1622. [PMID: 24060436 DOI: 10.1016/j.jvir.2013.07.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
221 Washburn K. Model for End Stage Liver Disease and hepatocellular carcinoma: a moving target. Transplant Rev (Orlando). 2010;24:11-17. [PMID: 19942101 DOI: 10.1016/j.trre.2009.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
222 Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010;3:55-66. [PMID: 21180590 DOI: 10.1177/1756283x09346669] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
223 Ofosu A, Gurakar A. Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. Euroasian J Hepatogastroenterol 2015;5:19-25. [PMID: 29201680 DOI: 10.5005/jp-journals-10018-1123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
224 Ravaioli M, Grazi GL, Cescon M, Ercolani G, Pinna AD, Piscaglia F, Trevisani F. Down-Staging of Hepatocellular Carcinoma Before Liver Transplantation: Should We Change Our Clinical Practice? Annals of Surgery 2009;250:348. [DOI: 10.1097/sla.0b013e3181b1e72a] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
225 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017;67:173-83. [DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 17.3] [Reference Citation Analysis]
226 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
227 Trinchet J. Carcinome hépatocellulaire : une incidence croissante, une prise en charge « optimisée ». Gastroentérologie Clinique et Biologique 2009;33:830-9. [DOI: 10.1016/j.gcb.2009.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
228 Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol 2015; 21(36): 10327-10335 [PMID: 26420959 DOI: 10.3748/wjg.v21.i36.10327] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
229 Agopian VG, Morshedi MM, Mcwilliams J, Harlander-locke MP, Markovic D, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Hiatt JR, Busuttil RW. Complete Pathologic Response to Pretransplant Locoregional Therapy for Hepatocellular Carcinoma Defines Cancer Cure After Liver Transplantation: Analysis of 501 Consecutively Treated Patients. Annals of Surgery 2015;262:536-45. [DOI: 10.1097/sla.0000000000001384] [Cited by in Crossref: 69] [Cited by in F6Publishing: 37] [Article Influence: 11.5] [Reference Citation Analysis]
230 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5(6): 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
231 Rubinstein MM, Kaubisch A, Kinkhabwala M, Reinus J, Liu Q, Chuy JW. Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. J Gastrointest Oncol 2017;8:1051-5. [PMID: 29299366 DOI: 10.21037/jgo.2017.08.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
232 Nasser F, Cavalcante RN, Galastri FL, de Rezende MB, Felga GG, Travassos FB, De Fina B, Affonso BB. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. J Vasc Interv Radiol. 2014;25:1012-1017. [PMID: 24704346 DOI: 10.1016/j.jvir.2014.02.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
233 Kardashian A, Florman SS, Haydel B, Ruiz RM, Klintmalm GB, Lee DD, Taner CB, Aucejo F, Tevar AD, Humar A, Verna EC, Halazun KJ, Chapman WC, Vachharajani N, Hoteit M, Levine MH, Nguyen MH, Melcher ML, Langnas AN, Carney CA, Mobley C, Ghobrial M, Amundsen B, Markmann JF, Sudan DL, Jones CM, Berumen J, Hemming AW, Hong JC, Kim J, Zimmerman MA, Nydam TL, Rana A, Kueht ML, Fishbein TM, Markovic D, Busuttil RW, Agopian VG. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. Hepatology. 2020;72:2014-2028. [PMID: 32124453 DOI: 10.1002/hep.31210] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
234 Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19(43): 7515-7530 [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 57] [Article Influence: 8.6] [Reference Citation Analysis]
235 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
236 Kornberg A, Witt U, Küpper B, Wildgruber M, Friess H. Postinterventional tumor necrosis predicts recurrence-free long-term survival in liver transplant patients with advanced hepatocellular carcinoma. Transplant Proc 2013;45:1913-5. [PMID: 23769071 DOI: 10.1016/j.transproceed.2013.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
237 Washburn K, Halff G. Hepatocellular carcinoma and liver transplantation. Curr Opin Organ Transplant. 2011;16:297-300. [PMID: 21505342 DOI: 10.1097/mot.0b013e3283465756] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
238 Di Benedetto F, Tarantino G, Ercolani G, Baccarani U, Montalti R, De Ruvo N, Berretta M, Adani GL, Zanello M, Tavio M. Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. Oncologist. 2013;18:592-599. [PMID: 23666950 DOI: 10.1634/theoncologist.2012-0255] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
239 Finotti M, Vitale A, Volk M, Cillo U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:885-900. [PMID: 32662680 DOI: 10.1080/17474124.2020.1791704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
240 Gilbo N, Van Praet L, Jochmans I, Sainz-barriga M, Verslype C, Maleux G, Laleman W, van der Merwe S, Cassiman D, Nevens F, Monbaliu D, Pirenne J. Pre-operative trans-catheter arterial chemo-embolization increases hepatic artery thrombosis after liver transplantation - a retrospective study. Transpl Int 2018;31:71-81. [DOI: 10.1111/tri.13046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
241 Reataza M, Imagawa DK. Advances in managing hepatocellular carcinoma. Front Med. 2014;8:175-189. [PMID: 24810646 DOI: 10.1007/s11684-014-0332-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
242 Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, Kim DG, Choi JY. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther. 2010;31:415-423. [PMID: 19821808 DOI: 10.1111/j.1365-2036.2009.04167.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
243 Castelli G, Burra P, Giacomin A, Vitale A, Senzolo M, Cillo U, Farinati F. Sorafenib use in the transplant setting. Liver Transpl. 2014;20:1021-1028. [PMID: 24809799 DOI: 10.1002/lt.23911] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
244 Shirabe K, Taketomi A, Morita K, Soejima Y, Uchiyama H, Kayashima H, Ninomiya M, Toshima T, Maehara Y. Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transplant. 2011;25:E491-E498. [PMID: 21518000 DOI: 10.1111/j.1399-0012.2011.01463.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
245 Gupta AA, Gerstle JT, Ng V, Wong A, Fecteau A, Malogolowkin MH, Meyers RL, Grant D, Grant RM. Critical review of controversial issues in the management of advanced pediatric liver tumors: Advanced Pediatric Liver Tumors. Pediatr Blood Cancer 2011;56:1013-8. [DOI: 10.1002/pbc.22893] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
246 Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: Percutaneous and open approaches. J Surg Oncol. 2009;100:619-634. [PMID: 20017157 DOI: 10.1002/jso.21364] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
247 Yegin EG, Oymaci E, Karatay E, Coker A. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary & Pancreatic Diseases International 2016;15:234-56. [DOI: 10.1016/s1499-3872(16)60097-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
248 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
249 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
250 Kim JM, Kwon CH, Joh JW, Kim SJ, Shin M, Kim EY, Moon JI, Jung GO, Choi GS, Lee SK. Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation? Transplant Proc 2010;42:821-4. [PMID: 20430181 DOI: 10.1016/j.transproceed.2010.02.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
251 Fidelman N, Kerlan RK Jr. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease. AJR Am J Roentgenol 2015;205:742-52. [PMID: 26397322 DOI: 10.2214/AJR.15.14802] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
252 Labadie KP, Schaub SK, Khorsand D, Johnson G, Apisarnthanarax S, Park JO. Multidisciplinary approach for multifocal, bilobar hepatocellular carcinoma: A case report and literature review. World J Hepatol 2019; 11(1): 119-126 [PMID: 30705724 DOI: 10.4254/wjh.v11.i1.119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Marshall AE, Rushbrook SM, Vowler SL, Palmer CR, Davies RJ, Gibbs P, Davies SE, Coleman N, Alexander GJ. Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl. 2010;16:279-288. [PMID: 20209638 DOI: 10.1002/lt.21993] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
254 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 808] [Article Influence: 112.9] [Reference Citation Analysis]
255 Takada Y, Tohyama T, Watanabe J. Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepatobiliary Pancreat Sci 2015;22:279-86. [PMID: 25408520 DOI: 10.1002/jhbp.195] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
256 Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK Jr, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968-1977. [PMID: 25689978 DOI: 10.1002/hep.27752] [Cited by in Crossref: 217] [Cited by in F6Publishing: 176] [Article Influence: 36.2] [Reference Citation Analysis]
257 Iwamoto S, Yamaguchi T, Hongo O, Iwamoto H, Sanefuji H. Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinoma: A retrospective study of local recurrence and long-term survival rates in 120 patients with hepatocellular carcinoma. Cancer 2010;116:393-9. [DOI: 10.1002/cncr.24678] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
258 Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15): 4115-4127 [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 237] [Cited by in F6Publishing: 220] [Article Influence: 33.9] [Reference Citation Analysis]
259 Mancuso A, Mazzola A, Cabibbo G, Perricone G, Enea M, Galvano A, Zavaglia C, Belli L, Cammà C. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. Dig Liver Dis 2015;47:324-30. [PMID: 25641331 DOI: 10.1016/j.dld.2015.01.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
260 Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation. 2014;98:100-106. [PMID: 24503764 DOI: 10.1097/01.tp.0000441090.39840.b0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
261 Lei J, Yan L. Comparison between living donor liver transplantation recipients who met the Milan and UCSF criteria after successful downstaging therapies. J Gastrointest Surg. 2012;16:2120-2125. [PMID: 22948843 DOI: 10.1007/s11605-012-2019-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
262 Ma KW, Chok KSH, Fung JYY, Lo CM. Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong. J Clin Transl Hepatol 2018;6:283-8. [PMID: 30271740 DOI: 10.14218/JCTH.2017.00058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Dendy MS, Camacho JC, Ludwig JM, Krasinskas AM, Knechtle SJ, Kim HS. Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence. Transplant Direct 2017;3:e206. [PMID: 28894793 DOI: 10.1097/TXD.0000000000000707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
264 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 90] [Article Influence: 12.4] [Reference Citation Analysis]
265 Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017; 23(20): 3690-3701 [PMID: 28611522 DOI: 10.3748/wjg.v23.i20.3690] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
266 Degroote H, Piñero F, Costentin C, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas AL, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Di Benedetto F, Duque SH, Salame E, Cillo U, Gadano A, Vanlemmens C, Fagiuoli S, Rubinstein F, Burra P, Cherqui D, Silva M, Van Vlierberghe H, Duvoux C; French-Italian-Belgium and Latin American collaborative group for HCC and liver transplantation. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. JHEP Rep 2021;3:100331. [PMID: 34485882 DOI: 10.1016/j.jhepr.2021.100331] [Reference Citation Analysis]
267 Hodgson A, Almansouri Z, Adeyi O, Fischer SE. Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. J Clin Pathol 2019;72:112-9. [PMID: 30670563 DOI: 10.1136/jclinpath-2018-205596] [Reference Citation Analysis]
268 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
269 Liu S, Miao J, Shi X, Wu Y, Jiang C, Zhu X, Wu X, Ding Y, Xu Q. Risk Factors for Post-Transplant Death in Donation after Circulatory Death Liver Transplantation. J Invest Surg 2018;31:393-401. [PMID: 28829664 DOI: 10.1080/08941939.2017.1339152] [Reference Citation Analysis]
270 DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253:166-172. [PMID: 21294289 DOI: 10.1097/sla.0b013e31820508f1] [Cited by in Crossref: 170] [Cited by in F6Publishing: 90] [Article Influence: 17.0] [Reference Citation Analysis]
271 Jiang L, Lei JY, Wang WT, Yan LN, Li B, Wen TF, Xu MQ, Yang JY, Wei YG. Immediate Radical Therapy or Conservative Treatments When Meeting the Milan Criteria for Advanced HCC Patients After Successful TACE. J Gastrointest Surg 2014;18:1125-30. [DOI: 10.1007/s11605-014-2508-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
272 Victor DW 3rd, Monsour HP Jr, Boktour M, Lunsford K, Balogh J, Graviss EA, Nguyen DT, McFadden R, Divatia MK, Heyne K, Ankoma-Sey V, Egwim C, Galati J, Duchini A, Saharia A, Mobley C, Gaber AO, Ghobrial RM. Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience. Transplantation. 2020;104:113-121. [PMID: 31233480 DOI: 10.1097/tp.0000000000002835] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
273 Cascales Campos P, Ramirez P, Gonzalez R, Febrero B, Pons JA, Miras M, Sanchez Bueno F, Robles R, Parrilla P. Value of 18-FDG-positron emission tomography/computed tomography before and after transarterial chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: initial results. Transplant Proc. 2011;43:2213-2215. [PMID: 21839236 DOI: 10.1016/j.transproceed.2011.05.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
274 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A;  OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(11)70175-9] [Cited by in Crossref: 600] [Cited by in F6Publishing: 233] [Article Influence: 60.0] [Reference Citation Analysis]
275 Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep. 2011;13:186-194. [PMID: 21409527 DOI: 10.1007/s11912-011-0165-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
276 Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocellular carcinoma. Int J Hepatol. 2013;2013:419302. [PMID: 24455285 DOI: 10.1155/2013/419302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
277 Zaydfudim VM, Vachharajani N, Klintmalm GB, Jarnagin WR, Hemming AW, Doyle MB, Cavaness KM, Chapman WC, Nagorney DM. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg 2016;264:650-8. [PMID: 27433910 DOI: 10.1097/SLA.0000000000001866] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
278 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 181] [Article Influence: 16.5] [Reference Citation Analysis]
279 Seinstra BA, van Delden OM, van Erpecum KJ, van Hillegersberg R, Mali WP, van den Bosch MA. Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging. 2010;1:167-181. [PMID: 23100194 DOI: 10.1007/s13244-010-0027-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
280 Sandow TA, Arndt SE, Albar AA, DeVun DA, Kirsch DS, Gimenez JM, Bohorquez HE, Gilbert PJ, Thevenot PT, Nunez KG, Galliano GA, Cohen AJ, Kay D, Gulotta PM. Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort. Radiology 2018;286:1072-83. [PMID: 29206595 DOI: 10.1148/radiol.2017170731] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
281 Takamura H, Nakanuma S, Hayashi H, Tajima H, Kakinoki K, Sakai S, Makino I, Nakagawara H, Miyashita T, Okamoto K, Nakamura K, Oyama K, Inokuchi M, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Ohnishi I, Kayahara M, Tani T, Arai K, Yamashita T, Yamashita T, Kitamura H, Ikeda H, Kaneko S, Nakanuma Y, Matsui O, Ohta T. Evaluation of eligibility criteria in living donor liver transplantation for hepatocellular carcinoma by α-SMA-positive cancer-associated fibroblasts. Oncol Rep 2013;30:1561-74. [PMID: 23863893 DOI: 10.3892/or.2013.2616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
282 Cunha GM, Hosseini M, Furlan A, Fowler KJ. Hepatocellular Carcinoma Staging: Differences Between Radiologic and Pathologic Systems and Relevance to Patient Selection and Outcomes in Liver Transplantation. AJR Am J Roentgenol 2021;:1-10. [PMID: 34406054 DOI: 10.2214/AJR.21.26436] [Reference Citation Analysis]
283 Patel SS, Arrington AK, McKenzie S, Mailey B, Ding M, Lee W, Artinyan A, Nissen N, Colquhoun SD, Kim J. Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States. Int J Hepatol. 2012;2012:253517. [PMID: 22957260 DOI: 10.1155/2012/253517] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
284 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016; 8(1): 58-68 [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
285 Charalel RA, Mcginty G, Brant-zawadzki M, Goodwin SC, Khilnani NM, Matsumoto AH, Min RJ, Soares GM, Cook PS. Interventional Radiology Delivers High-Value Health Care and Is an Imaging 3.0 Vanguard. Journal of the American College of Radiology 2015;12:501-6. [DOI: 10.1016/j.jacr.2014.10.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
286 Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014;8:71-6. [PMID: 24899827 DOI: 10.4137/CMO.S9926] [Cited by in Crossref: 90] [Cited by in F6Publishing: 54] [Article Influence: 12.9] [Reference Citation Analysis]
287 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 172] [Article Influence: 24.1] [Reference Citation Analysis]
288 Eguchi S, Hidaka M, Tomonaga T, Miyazaki K, Inokuma T, Takatsuki M, Okudaira S, Yamanouchi K, Miyaaki H, Ichikawa T, Tajima Y, Kanematsu T. Actual therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation. J Gastroenterol 2009;44:624-9. [PMID: 19381752 DOI: 10.1007/s00535-009-0043-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
289 Varghese J, Kedarisetty CK, Venkataraman J, Srinivasan V, Deepashree T, Uthappa MC, Ilankumaran K, Govil S, Srinivas Reddy M, Rela M. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience. Annals of Hepatology 2017;16:247-54. [DOI: 10.5604/16652681.1231585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
290 Jeng KS, Huang CC, Lin CK, Lin CC, Huang CT, Chung CS, Weng MT, Chen KH. Reappraisal of Failures in Downstaging Treatment of Hepatocellular Carcinoma Prior to Liver Transplant-Preliminary Report on the Impact of Underestimations of Tumor Numbers and Tumor Sizes as Measured From Imaging Before Transplant. Transplant Proc 2019;51:1428-34. [PMID: 31079940 DOI: 10.1016/j.transproceed.2019.03.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
291 Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018;73:369-85. [DOI: 10.1111/his.13520] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
292 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
293 Palmer WC, Lee D, Burns J, Croome K, Rosser B, Patel T, Keaveny AP, Pungpapong S, Satyanarayana R, Yataco M, Nakhleh R, Musto KR, Canabal AM, Turnage AK, Hodge DO, Nguyen JH, Harnois DM. Liver Transplantation for Hepatocellular Carcinoma: Impact of Wait Time at a Single Center. Annals of Hepatology 2017;16:402-11. [DOI: 10.5604/01.3001.0009.8595] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
294 Ho M, Yu C, Chung K, Chen T, Chu H, Lin C, Hsieh C. Locoregional Therapy-Induced Tumor Necrosis as a Predictor of Recurrence after Liver Transplant in Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2011;18:3632-9. [DOI: 10.1245/s10434-011-1803-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
295 Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, Cioni R, Filipponi F, Bartolozzi C. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82:e212-e218. [PMID: 23332890 DOI: 10.1016/j.ejrad.2012.12.009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
296 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 684] [Article Influence: 62.2] [Reference Citation Analysis]
297 Affonso BB, Galastri FL, da Motta Leal Filho JM, Nasser F, Falsarella PM, Cavalcante RN, de Almeida MD, Felga GEG, Valle LGM, Wolosker N. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J Gastroenterol 2019; 25(37): 5687-5701 [PMID: 31602168 DOI: 10.3748/wjg.v25.i37.5687] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
298 Tang A, Fowler KJ, Chernyak V, Chapman WC, Sirlin CB. LI-RADS and transplantation for hepatocellular carcinoma. Abdom Radiol 2018;43:193-202. [DOI: 10.1007/s00261-017-1210-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
299 Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:S277-S282. [PMID: 15508095 DOI: 10.1007/978-1-60327-376-3_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
300 D'souza S, Lau KCK, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol 2020; 26(38): 5759-5783 [PMID: 33132633 DOI: 10.3748/wjg.v26.i38.5759] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
301 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
302 Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl. 2011;17 Suppl 2:S109-S116. [PMID: 21584927 DOI: 10.1002/lt.22335] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
303 Akoad ME, Pomfret EA. Surgical Resection and Liver Transplantation for Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:381-99. [DOI: 10.1016/j.cld.2015.01.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
304 Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease 2013;45:712-23. [DOI: 10.1016/j.dld.2013.01.012] [Cited by in Crossref: 103] [Cited by in F6Publishing: 113] [Article Influence: 12.9] [Reference Citation Analysis]
305 Braat MN, Samim M, van den Bosch MA, Lam MG. The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging 2016;4:283-95. [PMID: 27512689 DOI: 10.1007/s40336-016-0172-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
306 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014; 20(30): 10223-10237 [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
307 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 702] [Article Influence: 345.0] [Reference Citation Analysis]
308 Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44-S57. [PMID: 21695773 DOI: 10.1002/lt.22365] [Cited by in Crossref: 320] [Cited by in F6Publishing: 295] [Article Influence: 35.6] [Reference Citation Analysis]
309 Eswaran SL, Pierce K, Weaver F, Rogers T, Brems JJ, Sontag SJ, Borge M. Transarterial chemoembolization for HCC in patients with extensive liver transplantation waiting times. Angiology 2012;63:206-12. [PMID: 21733955 DOI: 10.1177/0003319711411705] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
310 Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl. 2011;17:934-942. [PMID: 21438129 DOI: 10.1002/lt.22307] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 12.7] [Reference Citation Analysis]
311 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
312 Guba M, Angele M, Rentsch M, Jauch KW, Zachoval R, Kolligs F, Gerbes A, Bruns CJ. [Therapy of hepatocellular carcinoma before liver transplantation]. Chirurg 2013;84:385-90. [PMID: 23519379 DOI: 10.1007/s00104-012-2415-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
313 Jeng KS, Huang CC, Chung CS, Lin CK, Teng CJ, Shueng PW, Chen KH. Transplantation After Successful Downstaging by Multimodal Treatments of American Joint Committee on Cancer Stage IIIB Hepatocellular Carcinoma With Portal Vein Thrombi: A Case Report. Transplant Proc 2018;50:2882-4. [PMID: 30401416 DOI: 10.1016/j.transproceed.2017.11.081] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
314 Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:423-32. [DOI: 10.1038/nrgastro.2009.86] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 6.7] [Reference Citation Analysis]
315 Kampalath R, Tran-Harding K, Do RKG, Mendiratta-Lala M, Yaghmai V. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magn Reson Imaging Clin N Am 2021;29:389-403. [PMID: 34243925 DOI: 10.1016/j.mric.2021.05.013] [Reference Citation Analysis]
316 Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant 2009;23 Suppl 21:49-60. [PMID: 19930317 DOI: 10.1111/j.1399-0012.2009.01110.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
317 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 254] [Article Influence: 83.6] [Reference Citation Analysis]
318 Miltiadous O, Sia D, Hoshida Y, Fiel MI, Harrington AN, Thung SN, Tan PS, Dong H, Revill K, Chang CY, Roayaie S, Byrne TJ, Mazzaferro V, Rakela J, Florman S, Schwartz M, Llovet JM. Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. Journal of Hepatology 2015;63:1368-77. [DOI: 10.1016/j.jhep.2015.07.025] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]